Issues
-
Cover Image
Cover Image
Circular RNAs (circRNA) are noncoding RNAs that have diverse roles in cancer development and progression. Wang et al. find that circATP2B4 is associated with the development and progression of epithelial ovarian cancer. Epithelial ovarian cancer cells release circATP2B4 in extracellular vesicles, which leads to M2 macrophage polarization, immunosuppression, and enhanced metastasis. These data identify a new circRNA and its functions in epithelial ovarian cancer, suggesting new avenues of research for developing diagnostic and therapeutic targets for this devastating disease. Read more in this issue on page 199. Original image from Fig. 7D. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We're Reading
In the Spotlight
Meeting Report
Priority Briefs
Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR
Rational protein design yielded a CD20 CAR that outperforms a clinically relevant CD19 CAR in lymphoma models, providing a new candidate for non-Hodgkin lymphoma therapy. This protein-engineering approach could be applied to develop additional CARs against diverse antigens.
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
The authors find a correlation between abundance of self-renewing CD8+ T cells in blood and response of cancer patients to PD-1 blockade, suggesting assessment of T-cell regenerative status might serve as a noninvasive, predictive biomarker of immunotherapy response.
Research Articles
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells
NKT cells employ an undefined mechanism to undergo central memory–like differentiation, which is associated with increased antitumor potential. The authors demonstrate that LEF1 drives central memory programming in human NKTs, informing rational design of NKT-based cancer immunotherapy.
Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
A combination of naked mRNAs encoding IL12 and IL18 is efficacious upon intratumoral injection but is toxic if lipo-formulated and given systemically. A nonrepressible IL18 mutant markedly increases local abundance of IFNγ and enhances immunotherapeutic efficacy.
Extracellular Vesicle–Packaged circATP2B4 Mediates M2 Macrophage Polarization via miR-532-3p/SREBF1 Axis to Promote Epithelial Ovarian Cancer Metastasis
circATP2B4 is found to be associated with the development and progression of epithelial ovarian cancer. Extracellular vesicle-packaged circATP2B4 induces macrophage M2 polarization and cancer cell metastasis via SREBF1/PI3Kα/AKT signaling, suggesting a role as a diagnostic and therapeutic target.
Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
In mice with checkpoint-refractory melanoma, antigen-loaded EVs induce antitumor immune responses. Prophylactic immunization with EVs sensitizes tumors to anti–PD-L1 and leads to prolonged survival, indicating potential use of EVs against checkpoint-refractory cancers.
HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti–PD-1 Treatment Efficacy
Small extracellular vesicles containing PD-L1 secreted by tumor cells can inhibit host immunity, preventing tumor cell killing. HRS is identified as a regulator of PD-L1+ small extracellular vesicle secretion, therefore presenting a potential target for enhancing immunotherapy.
Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
The authors show that tumor or host CMTM6 deficiency can promote cytotoxicity-dependent antitumor immune responses, even in the absence of the PD-1/PD-L1 axis. The data suggest CMTM6 as a novel target for oncoimmunology gene therapy and combination treatment.
Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice
A therapeutic HPV16 vaccine consisting of E1, E2, E6 and E7 viral antigens delivered by adenoviral vectors is shown to suppress the growth of HPV16-positive transplanted tumors in mice, especially when used together with cisplatin.
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.